532 / 1835
Effector
cell
ADCC, antibody-dependent cell-mediated cytotoxicity; CDC, complement-dependent cytotoxicity
FcγRIIIa
Complement
Increased direct cell death
Type II antibody & elbow-hinge modification
Increased ADCC
Higher affinity to the 'ADCC receptor' FcγRIIIa
(GlycoMab TM technology) &
Reduced CD20 internalization (?)
Reduced CDC activity
Type II antibody
Enhanced activity in combination with
chemotherapy
Type II CD20 antibody
Putative mechanism(s) of action